Coronavirus Notebook: UK Adds Paxlovid To PANORAMIC Study, Germany Funds Adrecizumab Phase II Trial
RedHill’s opaganib has shown “potent inhibition” of the Omicron variant in early studies, while the EMA has found no links between the mRNA vaccines and autoimmune hepatitis.
You may also be interested in...
FDA Commissioner’s recent Twitter threads highlight the challenges of discussing the unknowns of therapeutic interventions – and raise questions about why FDA isn’t doing more to close the information gaps.
As work continues on vaccines adapted to tackle variants of SARS-CoV-2, the EU regulator says the decision-making on such products should take place at a global level.
From next year, more agencies will be involved in the UK’s regulatory reliance procedure for new drug approvals, which was first introduced in 2021 to allay fears of post-Brexit delays to UK applications. The pharmaceutical industry said it looked forward to working with the regulator on the new framework.